James Wilmott
The University of Sydney Library, NHMRC, The University of Sydney, Melanoma Institute Australia
Research areas: Medicine · Oncology · Cutaneous Melanoma Detection and Management · Cancer Immunotherapy and Biomarkers · Melanoma and MAPK Pathways
0000-0002-6750-5244
About
Dr Wilmott is a current NHMRC research fellow, 2020 NHMRC investigator fellow, senior lecturer at The University of Sydney and research leader of the Melanoma Translational Pathology Research Group (MTPRG) at the Charles Perkins Center, The University of Sydney. Dr Wilmott leads the large 25+ research team whose research interests spans areas such as primary melanoma diagnosis, melanoma biology, systemic therapies in advanced disease and more recently the development of personalized immunotherapies for metastatic melanoma.
Dr Wilmott is internationally recognized as an emerging expert in clinical implications of genomic profiles (First author Nature and Int J Cancer), immune profiling of cancer tissue (Co-author in Nature, The Lancet Oncology, senior author in Clinical Cancer Research and Oncoimmunology) and in biomarker discovery of systemic therapies (Senior author Cancer Cell). Dr Wilmott co-leads multople international programs of research that have made significant contributions to the knowledge in the melanoma genomics. This includes research that has described in unprecedented detail the somatic mutations that occur in a large cohort of cutaneous melanomas and melanomas that have arisen in mucosal (female genital and anorectal tract), acral (hands and feet) and the critical unmet need of childhood melanoma. This work has generated new knowledge with multiple publications (including in Nature, Laboratory Investigation, Oncotarget, J Invest Derm, Int J Cancer and Pathology). I am a significant contributor to this body of work as reflected by the first or senior authorship on 6/7 publications and contributed funding as CIA on grants focusing on childhood melanoma.
A major focus of Dr Wilmott’s research is the integrate clinical, multi-omic and pathological data into the selection of systemic therapies for metastatic melanoma patients. Dr Wilmott is a world leader in highly multiplexed immune profiling in melanoma patients’ tissue and the correlates with transcriptomics and clinical response to immunotherapies (Cancer Cell 2019). Dr Wilmott has experience in immunotherapy drug discovery in melanoma biopsies (Clin Cancer Res 2019) and his work applies the above skills and expertise to uncover effective treatment options for the more that 50% of melanoma patients not responding to current therapies.
Employment
-
The University of Sydney Library Associate Professor2022 - Present
-
NHMRC Investigator Fellow2020 - Present
-
National Health and Medical Research Council Early career research fellow2016 - 2019
-
The University of Sydney Senior Lecturer2015 - 2022
-
Melanoma Institute Australia Research Leader2013 - Present
Education
- 2009 - 2013
- 2001 - 2008
Projects & Funding
-
Personalised Immunotherapy Program – Precision immunotherapies for multiple solid tumours using a biomarker driven adaptive enrichment clinical trials platform Cancer Council NSW2022 - 2026
-
Effective therapies for patients with high risk in-transit disease Melanoma Research Alliance2019 - 2023
-
Rational clinical trial design and treatment selection for advanced cancer patients. National Health and Medical Research Council2019 - Present
-
Melanotransferrin: A â Missing Linkâ and a Novel Pharmacological Target for Treatment National Health and Medical Research Council2018 - 2020
-
The mutational landscape of melanoma in adolescents and young adults National Health and Medical Research Council2016 - 2019
-
Identifying novel therapeutic targets for the treatment of melanoma in adolescents and young adults Cancer Institute of New South Wales2015 - Present
Publications (462)
- Deep Learning Framework for Classifying Whole-Slide Multiplex Immunofluorescence Images to Predict Immunotherapy Response in Melanoma Patients Save
- Site-specific metabolic and hypoxia-associated profiles in metastatic melanoma Save
- NeoIRENIE: A phase 2 randomized trial of intensified neoadjuvant therapy for melanoma patients with multi-omic biomarker or clinically predicted poor response to standard immune checkpoint inhibitor (ICI) therapy. Save
- Analytical Characterization of Driver Mutation Detection across Two NGS Panels in Melanocytic Tumors Save
- Image Quality Assessment of Imputation-Induced Biomarker Distortions in Multiplex Immunofluorescence Save
- Abstract 2883: Divergent gut microbial communities are linked to differences in baseline immune profiles, tumor features and ICI outcomes in melanoma Save
- A randomised pilot trial of perioperative propranolol combined with celecoxib versus standard of care in stage III melanoma: The ProCel study protocol Save
- A-241 Genomic Profiling to Predict Immunotherapy Response in Merkel Cell Carcinoma Save
- Molecular Profiling and Matched Targeted Therapy for Patients With Advanced Melanoma: Results From Part 1 of the MatchMEL Study Save
- Data from Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases Save
- Supplementary Figure S1 from Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases Save
- Supplementary Tables S1-7 from Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases Save
- Factors Associated With Implementation of Biomarker Testing and Strategies to Improve Its Clinical Uptake in Cancer Care: Systematic Review Using Theoretical Domains Framework Save
- Data from Discovery and Validation of an Ancillary Genomic Test of Malignancy for Primary Melanocytic Tumors Save
- Discovery and Validation of an Ancillary Genomic Test of Malignancy for Primary Melanocytic Tumors Save
- Figure S1 from Discovery and Validation of an Ancillary Genomic Test of Malignancy for Primary Melanocytic Tumors Save
- Figure S2 from Discovery and Validation of an Ancillary Genomic Test of Malignancy for Primary Melanocytic Tumors Save
- Figure S3 from Discovery and Validation of an Ancillary Genomic Test of Malignancy for Primary Melanocytic Tumors Save
- Figure S4 from Discovery and Validation of an Ancillary Genomic Test of Malignancy for Primary Melanocytic Tumors Save
- Figure S5 from Discovery and Validation of an Ancillary Genomic Test of Malignancy for Primary Melanocytic Tumors Save